Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $498,700.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $49.87, for a total value of $498,700.00. Following the completion of the sale, the insider now owns 95,648 shares in the company, valued at $4,769,965.76. The trade was a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.11, for a total value of $264,144.14.

Akero Therapeutics Stock Performance

Shares of AKRO stock opened at $51.84 on Monday. The company has a market capitalization of $3.62 billion, a P/E ratio of -13.82 and a beta of -0.11. The business’s 50 day moving average is $37.02 and its two-hundred day moving average is $31.79. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 12-month low of $17.86 and a 12-month high of $58.40.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. Morgan Stanley upped their target price on Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. Canaccord Genuity Group upped their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. HC Wainwright upped their target price on Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Finally, Citigroup increased their price target on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $75.86.

Hedge Funds Weigh In On Akero Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AKRO. Creative Planning purchased a new position in shares of Akero Therapeutics in the third quarter valued at approximately $371,000. Eastern Bank purchased a new position in shares of Akero Therapeutics in the third quarter valued at approximately $100,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Akero Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after acquiring an additional 446 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Akero Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,354 shares of the company’s stock valued at $383,000 after acquiring an additional 5,230 shares in the last quarter. Finally, Emerald Advisers LLC lifted its position in shares of Akero Therapeutics by 1.8% in the third quarter. Emerald Advisers LLC now owns 524,427 shares of the company’s stock valued at $15,046,000 after acquiring an additional 9,175 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.